Key Developments: Imperva Inc (IMPV.N)
41.87USD
19 Jun 2013
$0.51 (+1.23%)
$41.36
$41.42
$41.96
$41.42
83,819
43,770
$41.96
$24.02
Latest Key Developments (Source: Significant Developments)
Imperva Inc Issues Q2 2013 Guidance; Earnings Guidance Below Analysts' Estimates; Raises FY 2013 Revenue Guidance; Lowers FY 2013 Earnings Guidance
Imperva Inc announced that for the second quarter of 2013, it expects total revenue to be in the range of $31.0 million to $31.5 million, non-GAAP operating loss to be in the range of $(0.5) million to $(1.0) million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $(0.75) million to $(1.25) million, or a loss of $(0.03) to $(0.05) per share, which excludes stock-based compensation expense. For fiscal 2013, it expects total revenue to be in the range of $133.0 million to $137.0 million, non-GAAP operating profit to be in the range of $1.0 million to $3.0 million and non-GAAP net profit attributable to Imperva stockholders to be in the range of $0.5 million to $2.5 million, or $0.02 to $0.09 per share, which excludes stock-based compensation expense. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $31.4 million, EBIT of $0.44 million, net profit of $0.40 million and EPS of $0.02 for the second quarter of 2013; revenue of $133.2 million, EBIT of $5.35 million, net profit of $4.95 million and EPS of $0.19 for fiscal 2013. Full Article
Imperva Inc Issues Q1 2013 Mixed Guidance; Issues FY 2013 Guidance Above Analysts' Estimates
Imperva Inc announced that for the first quarter of 2013, it expects revenue to be in the range of $27.0 million to $27.5 million, non-GAAP operating loss to be in the range of $(2.0) million to $(2.5) million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $(2.25) million to $(2.75) million, or a loss of $(0.09) to $(0.11) per share, which excludes stock-based compensation expense. For fiscal 2013, it expects total revenue to be in the range of $131.0 million to $135.0 million, non-GAAP operating profit to be in the range of $5.0 million to $6.5 million and non-GAAP net profit attributable to Imperva stockholders to be in the range of $4.0 million to $5.0 million, or $0.15 to $0.21 per share, which excludes stock-based compensation expense. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $27.2 million, EBIT of $(0.09) million, net profit of $(0.15) and EPS of $(0.01) for the first quarter of 2013; revenue of $128.0 million, net profit of $6.7 million and EPS of $0.26 for fiscal 2013, Full Article
Imperva Inc Issues Q4 2012 Guidance; Revises FY 2012 Guidance
Imperva Inc announced that for the fourth quarter of 2012, it expects total revenue to be in the range of $29.5-$30.0 million, non-GAAP operating income to be in the range of $0.5 million to $0.8 million and non-GAAP net income to be in the range of $0.3 million to $0.6 million, or a profit of $0.01 to $0.02 per share, which excludes stock-based compensation expense. For fiscal 2012, it expects total revenue to be in the range of $102.0-$102.5 million, non-GAAP operating loss to be in the range of $1.8-$2.1 million and non-GAAP net loss to be in the range of $2.4 million to $2.7 million, or a loss of $0.11 to $0.12, which excludes stock-based compensation expense. Imperva expects capital expenditures for the full year to be in the range of $2.0 million to $2.5 million. Full Article
Imperva Inc Issues Q3, FY 2012 Guidance
Imperva Inc announced that for third quarter of 2012, it expects total revenue to be in the range of $24.6 million to $25.0 million, non-GAAP operating loss to be in the range of $0.5 million to $0.9 million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $0.4 million to $0.8 million, or a loss of $0.02 to $0.03 per share, which excludes stock-based compensation expense. For fiscal 2012, it expects total revenue to be in the range of $99.5 million to $101.5 million, non-GAAP operating loss to be in the range of $2.7 million to $3.1 million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $2.3 million to $2.7 million, or a loss of $0.11 to $0.13, which excludes stock-based compensation expense. Imperva expects capital expenditures for the full year to be in the range of $2.0 million to $2.5 million. Full Article
Imperva Inc Issues Q2 2012 Guidance; Lowers FY 2012 Revenue Guidance; Reaffirms FY 2012 Earnings Guidance
Imperva Inc announced that for the second quarter of 2012, it expects total revenue to be in the range of $23.3-$23.8 million, non-GAAP operating loss to be in the range of $1.2 million to $1.4 million and non-GAAP net loss to be in the range of $1.1-$1.3 million, or a loss of $0.04 to $0.05 per share, which excludes stock-based compensation expense. For fiscal 2012, it expects total revenue to be in the range of $98.0-$100.0 million, non-GAAP operating loss to be in the range of $3.3-$3.7 million and non-GAAP net loss to be in the range of $2.8-$3.2 million, or a loss of $0.12 to $0.14, which excludes stock-based compensation expense. Full Article
Imperva Inc Issues Q1 2012 Guidance; Issues FY 2012 Guidance In Line With Analysts' Estimates
Imperva Inc announced that for first quarter of 2012, it expects revenue for be in the range of $20.5 million to $21.0 million, non-GAAP operating loss to be in the range of $2.8 million to $3.0 million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $2.7 million to $2.9 million, or a loss of $0.12 to $0.13 per share, which excludes stock-based compensation expense. For fiscal 2012, the Company expects revenue to be in the range of $97.0 million to $99.0 million, non-GAAP operating loss to be in the range of $3.3 million to $3.7 million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $2.8 million to $3.2 million, or a loss of $0.12 to $0.14, which excludes stock-based compensation expense. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $97.7 million, operating loss of $3.5 million, net loss of $3.0 and loss per share of $0.13 for fiscal 2012. Full Article
Imperva Inc Sees IPO Priced At $14-$16/Share-Reuters
Reuters reported that Imperva Inc filed with U.S. regulators on Friday to price its Initial Public Offering (IPO) at $14-$16 per share. In June, Imperva had filed to raise up to $75 million in its common stock offering. Imperva has applied to list its shares on the New York Stock Exchange under the symbol 'IMPV'. The offering is being underwritten by J.P. Morgan, Deutsche Bank Securities, RBC Capital Markets, Lazard Capital Markets and Pacific Crest Securities. The stockholders of the company include entities associated with Accel Partners, Greylock Partners, U.S. Venture Partners and Venrock. Imperva plans to invest part of the proceeds generated in its majority-owned unit, Incapsula, it said in the filing. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
